11.1 Healthcare Regulations, Standards of Care, & Collaborative Practice

Healthcare Regulations, Standards of Care, & Collaborative Practice

FDA Drug Approval Process

The Food and Drug Administration (FDA) regulatory framework ensures the safety and efficacy of pharmaceutical products in the United States. The process begins with preclinical testing in animal models to determine pharmacokinetics, pharmacodynamics, and initial toxicity. If results are promising, an Investigational New Drug (IND) application is submitted to the FDA before human trials commence.

The clinical trial phase is delineated into four distinct phases:

• Phase I: Conducted in a small cohort (20-100) of healthy volunteers. The primary objective is to evaluate safety, determine the maximum tolerated dose (MTD), and understand the human pharmacokinetics of the compound.
• Phase II: Enrolls a larger group (100-300) of patients who have the target disease. The focus shifts to evaluating preliminary efficacy and optimal dosing regimens, while continuing to monitor safety.
• Phase III: The most rigorous phase, involving large, multicenter, randomized, double-blind, controlled trials with hundreds to thousands of patients. This phase establishes the drug's definitive clinical efficacy and identifies less common adverse events. Successful completion leads to a New Drug Application (NDA) or Biologics License Application (BLA).
• Phase IV: Post-marketing surveillance trials conducted after FDA approval. These observational studies monitor long-term safety, rare adverse effects in the general population, and cost-effectiveness. MedWatch is the FDA's voluntary reporting system for adverse events during this phase.

To expedite access to critical therapies, the FDA offers four expedited review pathways:

1. Fast Track: Facilitates the development of drugs treating serious conditions with unmet medical needs.
2. Breakthrough Therapy: For drugs showing substantial clinical improvement over existing therapies on a clinically significant endpoint in early trials.
3. Accelerated Approval: Allows approval based on a surrogate endpoint (e.g., tumor shrinkage) reasonably likely to predict clinical benefit.
4. Priority Review: Guarantees FDA review of the NDA within 6 months rather than the standard 10 months, reserved for drugs offering significant improvements in safety or effectiveness.

USP Compounding Standards

The United States Pharmacopeia (USP) establishes legally enforceable standards for pharmacy compounding, essential for maintaining preparation integrity and patient safety.

USP Chapter <795>: Nonsterile Compounding

USP <795> dictates the requirements for nonsterile preparations. It categorizes compounding into simple, moderate, and complex based on the level of expertise and specialized equipment required. A critical component is the assignment of Beyond-Use Dates (BUDs). For non-aqueous formulations, the BUD is the earliest expiration date of any API or 6 months. For water-containing oral formulations, the BUD is 14 days when stored at controlled cold temperatures. For water-containing topical/dermal formulations, the BUD is 30 days.

USP Chapter <797>: Sterile Compounding

USP <797> focuses on preventing microbial contamination during the preparation of compounded sterile preparations (CSPs). It mandates rigorous environmental controls, primarily International Organization for Standardization (ISO) classified environments. The primary engineering control (PEC), such as a laminar airflow workbench, must maintain ISO Class 5 air quality. The buffer area must be ISO Class 7, and the ante-area ISO Class 8 (or Class 7 if opening into a negative pressure room).

Recent revisions to USP <797> shifted from microbial risk levels (low, medium, high) to Categories 1, 2, and 3 based on the conditions under which they are made and the time within which they will be used. Category 1 CSPs have shorter BUDs (≤ 12 hours at room temperature or ≤ 24 hours refrigerated) and can be prepared in an unclassified segregated compounding area (SCA). Category 2 and 3 CSPs require a cleanroom suite and allow for longer BUDs, dependent on sterility testing and the use of preservatives.

USP Chapter <800>: Hazardous Drugs

USP <800> provides standards for the safe handling of hazardous drugs (HDs) to minimize exposure to healthcare personnel, patients, and the environment. HDs are defined by the National Institute for Occupational Safety and Health (NIOSH) based on characteristics like carcinogenicity, teratogenicity, and reproductive toxicity. Key requirements include:

• Storage of HDs in a negative-pressure room with at least 12 air changes per hour (ACPH).
• Compounding in a Containment Primary Engineering Control (C-PEC), such as a biological safety cabinet (BSC) or compounding aseptic containment isolator (CACI), located in a C-SEC (buffer room) maintaining negative pressure and at least 30 ACPH.
• Use of appropriate personal protective equipment (PPE), including double chemotherapy gloves and impermeable gowns.

Collaborative Practice Agreements (CPAs)

A Collaborative Practice Agreement (CPA) is a formal agreement between a licensed provider (typically a physician) and a pharmacist, allowing the pharmacist to assume delegated patient care responsibilities. CPAs are governed by state pharmacy practice acts, which vary significantly across jurisdictions.

Delegated functions often include initiating, modifying, or discontinuing pharmacotherapy, ordering and interpreting laboratory tests, and performing physical assessments. CPAs are foundational to the provision of Comprehensive Medication Management (CMM) and the integration of clinical pharmacists into primary care and specialty clinics.

Before executing a CPA, pharmacists typically undergo a rigorous credentialing and privileging process. Credentialing verifies the pharmacist's education, licensure, residency training (e.g., PGY1/PGY2), and board certification (e.g., BCPS, BCACP). Privileging is the process by which a healthcare organization authorizes a practitioner to perform a specific scope of patient care services within that institution, ensuring clinical competence aligns with the delegated tasks.

Quality and Accreditation Standards

Ensuring high-quality patient care requires adherence to standards established by major accrediting organizations.

The Joint Commission (TJC)

TJC evaluates and accredits healthcare organizations. A cornerstone of TJC accreditation is compliance with the National Patient Safety Goals (NPSGs). Key NPSGs highly relevant to pharmacy include:

• NPSG.03.04.01: Labeling all medications, medication containers, and other solutions on and off the sterile field in perioperative and other procedural settings.
• NPSG.03.05.01: Reducing the likelihood of patient harm associated with the use of anticoagulant therapy through standardized protocols and patient education.
• NPSG.03.06.01: Maintaining and communicating accurate patient medication information (Medication Reconciliation) at all transitions of care.

National Committee for Quality Assurance (NCQA)

The NCQA is instrumental in evaluating health plans and accountable care organizations. They develop and maintain the Healthcare Effectiveness Data and Information Set (HEDIS), a comprehensive tool utilized to measure performance on critical dimensions of care. Pharmacists frequently impact HEDIS measures such as:

• Comprehensive Diabetes Care (e.g., HbA1c control, statin therapy for patients with diabetes).
• Controlling High Blood Pressure.
• Medication Management for People with Asthma (MMPA).
• Adherence to antipsychotic medications for individuals with schizophrenia.

Pharmacist-led interventions targeted at improving HEDIS measures directly influence the quality ratings and financial reimbursement of health systems and managed care organizations.